Skip to main content

Pentavalent Meningococcal Conjugate vaccine

Award type :
Bridging Award
Product type :
Vaccines
Award year :
2024
Project start date :
07 / 23 / 2024
Project end date :
05 / 09 / 2025
Project duration (months) :
9
Development stage :
Phase 2
Target disease :
Meningitis
Region served :
Sub-Saharan Africa
Recipient organization / Country of funding recipient organization :
Eubiologics / Republic of Korea
Collaborator(s) / Country :
Program for Appropriate Technology in Health (PATH) / USA
Funding amount(KRW) :
4,000,000,000
Preceding project :
🔗Pentavalent Meningococcal Conjugate Vaccincce (BA 1)
Subsequent Project :
🔗Pentavalent Meningococcal Conjugate Vaccincce (BA 3)

NmCV-5, an affordable pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X for Sub-Saharan Africa’s Meningitis Belt, advanced into Phase 2, 3 trials in The Gambia and Mali across six age cohorts. Phase 2 results in Korea demonstrated safety and immunogenicity compared with existing quadrivalent vaccines. Enrollment across older age cohorts was completed, while enrollment in younger age groups was initiated, and interim safety and immunogenicity targets were met. The project continues under a Bridging Award through 2026, with MFDS approval expected in 2027.